BBOT FY 2024 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BBOTBridgeBio Oncology Therapeutics Inc.

$820M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$81M

Net Income

-$74M

EPS (Diluted)

$0.46

Cash Flow

Operating Cash Flow

-$763,820

Free Cash Flow

-$763,820

Stock-Based Comp.

$271,572

Balance Sheet

Total Assets

$194M

Total Liabilities

$6M

Stockholders' Equity

$189M

Cash & Equivalents

$2M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$81M	-$65M	-24.8%
Net Income	-$74M	-$65M	-14.8%